E
Barinthus Biotherapeutics plc BRNS
$0.823 $0.0070.86% NASDAQ
Recommendation
Prev Close
$0.823
Volume
25,645
Avg Vol (90D)
32,530
Market Cap
$33.20M
Dividend & Yield
--
52-Week Range
$0.64 - $2.60
P/E (TTM)
--
EPS (TTM)
-$1.56
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
4/11/2025 - Simply Wall St
Barinthus Bio Reports 2024 Financial Results and Strategic Focus
4/2/2025 - TipRanks Financial Blog
Barinthus Biotherapeutics price target lowered by $1.50 at Alliance Global Partners, here's why
3/24/2025 - The Fly
H.C. Wainwright Sticks to Its Buy Rating for Barinthus Biotherapeutics (BRNS)
3/21/2025 - TipRanks Financial Blog
Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Misses Expectations By $0.01 EPS
3/20/2025 - Ticker Report
Barinthus Biotherapeutics PLC Reports Q4 Revenue of $15.0M, EPS of $(1.55), Surpassing Estimates
3/20/2025 - GuruFocus
Barinthus Biotherapeutics sees cash runway into 2027
3/20/2025 - The Fly
Barinthus Biotherapeutics reports FY24 EPS ($1.55), consensus ($1.48)
3/20/2025 - The Fly
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
3/20/2025 - Globe Newswire
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update
3/18/2025 - Ticker Report
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
3/6/2025 - GuruFocus
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
3/6/2025 - Accesswire
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
1/31/2025 - Zacks Investment Research
Head to Head Comparison: Barinthus Biotherapeutics (NASDAQ:BRNS) & Arcus Biosciences (NYSE:RCUS)
1/22/2025 - Ticker Report
HC Wainwright Issues Pessimistic Forecast for Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Price
1/14/2025 - Ticker Report
Barinthus Biotherapeutics price target lowered by $2 at H.C. Wainwright, here's why
1/13/2025 - The Fly
Barinthus Biotherapeutics price target lowered by $2 at H.C. Wainwright, here's why
1/13/2025 - The Fly
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (IandI) and Provides a Financial Update
1/10/2025 - Globe Newswire
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Surges 33% Yet Its Low P/S Is No Reason For Excitement
1/10/2025 - Simply Wall St
Barinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed
11/25/2024 - TipRanks Financial Blog
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
11/25/2024 - Globe Newswire
HC Wainwright Reaffirms and#8220;Buy" Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)
11/23/2024 - Ticker Report
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%
11/19/2024 - Simply Wall St
Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
11/15/2024 - TipRanks Financial Blog
Barinthus announces results from ongoing Phase 2b HBV003 trial
11/15/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$14.97M
EBITDA (TTM)
-$43.33M
EBIT (TTM)
-$45.93M
Net Income (TTM)
-$61.07M
Balance Sheet
Total Assets (Q)
$160.33M
Total Debt (Q)
$12.01M
Total Liabilities (Q)
$30.19M
Book Value Per Share (Q)
$3.23
Cash Flow
Cash from Operations (TTM)
-$28.94M
Cash from Investing (TTM)
-$892.00K
Cash from Financing (TTM)
$2.16M
Net Change in Cash (TTM)
-$29.69M
Filings
Filing Date
Thursday, March 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
-0.15
7-Day Total Return
16.74%
30-Day Total Return
-22.36%
60-Day Total Return
-17.70%
90-Day Total Return
-9.81%
Year to Date Total Return
-33.63%
1-Year Total Return
-67.08%
2-Year Total Return
-64.98%
3-Year Total Return
-82.71%
5-Year Total Return
--
52-week Low
Apr 10, 2025 - $0.64
52-week High
Apr 26, 2024 - $2.60
Valuation
Market Cap
$33.20M - Nano Cap
Enterprise Value
-$65.35M
Price/Sales (TTM)
2.21
Price/Book (Q)
0.25
Dividends and Shares
Shares Outstanding
40.16M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.barinthusbio.com
Phone Number
44 1865 818 808
Address
Zeus Building
Unit 6-10 - Rutherford Avenue
Harwell Didcot, OX11 0DF
Country
United Kingdom
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome... more
NASDAQ 04/25/2025 3:59PM Eastern Quotes delayed